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A 3 years-old girl was referred to our department for prolonged oral bleeding following a mouth wound. She had no medical history of abnormal bleeding and her birth was normal.
There was no familial history of hemorrhage. Physical examination revealed many bruises.
Results of hemostatic tests of the propositus (Table 1 ) allowed diagnosis of VWD type 3 in the young girl. Paternal hemostatic tests were normal while the mother exhibited a mild deficiency of VWF, as is usually the case in carriers of VWD type 3 . 5
We gathered consent from each patient in order to carry out molecular genetic analysis. We We detected a homozygous 11pb deletion c.2574_2584del ( Figure 1 ) on exon 20 of the VWF gene in the proband DNA. To our knowledge, this mutation has never previously been described in publications or been referenced to sequence databases. This c.
2574_2584del results to a premature stop codon: p.Thr859ValfsX2. This frameshift mutation is clearly deleterious, leading to the truncation of the VWF protein or mRNA damage by nonsense mediated mRNA decay, which would explain the total plasma deficiency of VWF. The non-consanguineous parents of the patient were tested for the mutation by sequencing. We found a heterozygous 11pb deletion in the mother, and surprisingly, an absence of this mutation in the father. To test the hypothesis of uniparental disomy (UPD), 16 polymorphic genetic markers mapped to chromosome 12 were investigated. Every marker indicated a homozygosity of the entire chromosome 12 in the proband, consistent with maternal isodisomy. To our knowledge, there is no previous report of either paternal or maternal unidisomy involved in VWD. Interestingly, according to a recent review, 11 UPD of chromosome 12 has never been involved in an autosomal recessive disease case.
This case highlights the need to perform extensive molecular analysis of the VWF gene in VWD type 3 patients, in order to improve our knowledge of the molecular mechanisms and pathophysiology of the disease. Indeed, the discovery of a deletion leads a high risk factor for anti-VWF antibodies occurrence and may affect the therapeutic protocol for the patient.
Moreover, identifying an association between UPD of chromosome 12 and VWD is important with regard to genetic counseling for parents, in order to inform them about the negligible recurrence risk during a new pregnancy compared to the usual 25% risk related to an autosomal recessive transmission of type 3 VWD.
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